Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RXC 004

Next Previous
Drug Profile

RXC 004

Alternative Names: Porcupine inhibitor - Redx Pharma; RXC-004

Latest Information Update: 17 Jun 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Redx Pharma
  • Class Antifibrotics; Antineoplastics; Small molecules
  • Mechanism of Action PORCN protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Biliary cancer; Colorectal cancer; Pancreatic cancer
  • Phase I/II Solid tumours
  • No development reported Fibrosis

Most Recent Events

  • 05 Apr 2024 Adverse events data from a phase I/IIa trial in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
  • 02 Apr 2024 Redx Pharma completes a phase II trial in Colorectal cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater, Monotherapy, Combination therapy) in United Kingdom, Spain, South Korea, USA (PO) (NCT04907539) (EudraCT2020-003132-24)
  • 30 Nov 2023 Redx Pharma in collaboration with Merck & Co completes a phase II PORCUPINE2/KEYNOTE-E86 trial in Biliary cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Combination therapy, Second-line therapy or greater) in United Kingdom, Australia (PO) (NCT04907851)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top